![]() On the EORTC QLQ-C30 GHS/QoL and Functional Scales, improvements with pembrolizumab were especially notable for physical, emotional, and social functioning. Patients who previously received adjuvant chemotherapy said that pembrolizumab was much better tolerated for them.” “Many of my patients could continue working or function extremely well when on pembrolizumab compared to chemotherapy. “There were improved health-related quality-of-life scores with pembrolizumab vs chemotherapy,” Dr. Therefore, KEYNOTE-177 will remain blinded until 190 overall survival events are achieved or 12 months after the second interim analysis. The data monitoring committee recommended reporting overall survival at the final analysis, as it remains immature. ![]() “This translates to a median PFS2 of 23.5 months in the chemotherapy arm, whereas in the pembrolizumab arm, median PFS2 has not been reached.” PFS2 survival events were noted for 39% of the pembrolizumab arm vs 55% of the chemotherapy arm (HR = 0.63 95% confidence interval = 0.45–0.88). In the pembrolizumab arm, 56 patients had died vs 69 in the chemotherapy arm at the time of second interim analysis. “The curve clearly shows that there is still benefit from having pembrolizumab first, despite the fact that almost 60% of the chemotherapy arm crossed over to immunotherapy,” he said. Patients on the chemotherapy arm on disease progression received mostly pembrolizumab but also nivolumab, durvalumab, nivolumab plus ipilimumab, atezolizumab plus bevacizumab, and avelumab. In the pembrolizumab arm, 28.8% received subsequent therapy, primarily oxaliplatin-based regimens, although seven patients received pembrolizumab again, some as per protocol for disease relapse after completion of 2 years of first-line pembrolizumab. An additional 35 patients received a PD-1 inhibitor (anti–PD-1/PD-L1) outside of the study, for an effective crossover rate of 59% in the intent-to-treat population. Of 154 patients in the chemotherapy arm, 56 (36%) crossed over to receive pembrolizumab after confirmed disease progression. The duration of response was not reached with pembrolizumab and was 10.6 months with chemotherapy at the 2-year mark, 83% of the pembrolizumab arm were alive and responding, compared with 35% of the chemotherapy arm, Dr. At 24 months, 48.3% of the pembrolizumab arm was progression-free compared with 18.6% of the chemotherapy arm.Īs previously reported, almost all subgroups benefited more from pembrolizumab. In the final progression-free survival analysis, median progression-free survival was 16.5 months with pembrolizumab vs 8.2 with chemotherapy (HR = 0.60 P =. In the chemotherapy arm, six patients were ongoing at the time of data cutoff. There were 57 patients in the pembrolizumab arm who completed all their therapy, with 2 patients ongoing in treatment. For both cohorts, pembrolizumab at 200 mg every 3 weeks could be given for up to 35 cycles. The chemotherapy arm had the option of crossing over to pembrolizumab upon disease progression, as determined by independent blinded central review. KEYNOTE-177 included 307 patients with chemotherapy-naive MSI-H metastatic colorectal cancer who were randomly assigned to pembrolizumab or chemotherapy with or without bevacizumab or cetuximab by investigator’s choice. Shiu presented the analysis of second progression-free survival (PFS2), ie, the time from randomization to disease progression on the next line of therapy or death from any cause, and highlighted the health-related quality-of-life data for patients in the study. As reported at the 2020 ASCO Annual Meeting and recently published in The New England Journal of Medicine, 2 after a median follow-up of 32.4 months, median progression-free survival was 16.5 months with pembrolizumab and 8.2 months with chemotherapy (hazard ratio = 0.60 P =. In patients with metastatic MSI-H colorectal cancer, pembrolizumab has shown a clinical benefit in both previously treated and chemotherapy-naive patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |